Five Prime Therapeutics Inc (FPRX) Expected to Announce Quarterly Sales of $8.00 Million
Wall Street analysts predict that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report sales of $8.00 million for the current quarter, according to Zacks. Five analysts have made estimates for Five Prime Therapeutics’ earnings. The lowest sales estimate is $4.10 million and the highest is $13.42 million. Five Prime Therapeutics reported sales of $13.22 million during the same quarter last year, which indicates a negative year-over-year growth rate of 39.5%. The firm is expected to report its next quarterly earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Five Prime Therapeutics will report full-year sales of $52.48 million for the current fiscal year, with estimates ranging from $49.94 million to $53.84 million. For the next year, analysts forecast that the firm will post sales of $28.86 million, with estimates ranging from $7.30 million to $60.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). Five Prime Therapeutics had a negative net margin of 221.67% and a negative return on equity of 41.52%. The business had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $7.45 million.
Shares of FPRX opened at $11.26 on Wednesday. Five Prime Therapeutics has a 12 month low of $10.35 and a 12 month high of $27.61. The firm has a market cap of $410.34 million, a PE ratio of -2.09 and a beta of 3.23.
Hedge funds have recently modified their holdings of the stock. Price Capital Management Inc. purchased a new position in Five Prime Therapeutics in the 3rd quarter worth $118,000. Xact Kapitalforvaltning AB purchased a new position in Five Prime Therapeutics in the 3rd quarter worth $145,000. Granite Investment Partners LLC purchased a new position in Five Prime Therapeutics in the 3rd quarter worth $240,000. MetLife Investment Advisors LLC raised its stake in Five Prime Therapeutics by 48.7% in the 2nd quarter. MetLife Investment Advisors LLC now owns 19,957 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 6,535 shares during the last quarter. Finally, Alambic Investment Management L.P. purchased a new position in Five Prime Therapeutics in the 2nd quarter worth $351,000. Institutional investors own 83.03% of the company’s stock.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
Featured Story: Google Finance Portfolio Tips and Tricks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.